Presentation is loading. Please wait.

Presentation is loading. Please wait.

C-1 Microbiology Jeff Alder, Ph.D. Vice President, Drug Discovery and Evaluation Cubist Pharmaceuticals.

Similar presentations


Presentation on theme: "C-1 Microbiology Jeff Alder, Ph.D. Vice President, Drug Discovery and Evaluation Cubist Pharmaceuticals."— Presentation transcript:

1 C-1 Microbiology Jeff Alder, Ph.D. Vice President, Drug Discovery and Evaluation Cubist Pharmaceuticals

2 C-2 Analysis of MIC Shifts Unprecedented microbiology database Unprecedented microbiology database – 1,215 S. aureus isolates were tested for MICs – First study to examine serial isolate susceptibility in SAB patients MIC shifts to  2 noted MIC shifts to  2 noted – Daptomycin- and vancomycin-treated patients – Different susceptibility criteria Scientific investigations with these isolates Scientific investigations with these isolates – Bacteria, drug, patient

3 C-3 Wild-type Distribution of S. aureus Isolates Includes Daptomycin MICs of 2 µg/mL No. of Isolates MIC 90 (µg/mL) Range (µg/mL) MIC of 2 µg/mL n (%) Regional Surveys 1998-20035,2480.25 - 1  0.12 - 2 8 (0.15) Global Surveillance Studies 1999-20012,7870.25 - 0.5  0.12 - 2 1 (0.04) 20022,6230.5  0.12 - 2 2 (0.08) 20034,3620.5  0.12 - 2 1 (0.02) 20045,2600.5  0.12 - 2 2 (0.04) 20056,3740.5  0.12 - 2 3 (0.05) Total26,654NA  0.12 - 2 17 (0.06) MICs of 2 µg/mL were observed prior to approval (Sept ’03)MICs of 2 µg/mL were observed prior to approval (Sept ’03)

4 C-4 Daptomycin-treated Patients with Post-baseline Daptomycin MICs of 2 and 4 MIC 4 µg/mL (N = 1) MIC 4 µg/mL (N = 1) – 1 failure (cRIE; large septic pulmonary emboli, tunnel infection) MIC 2 µg/mL (N = 6) MIC 2 µg/mL (N = 6) – 1 success (cBAC; vertebral osteomyelitis, debrided x2) – 3 failures (cBAC; IV port infection, septic arthritis, retroperitoneal abscess) – 2 failures (LIE; no valve replacement surgery) Failed patients did not or could not receive adjunctive therapy (e.g., surgery, drainage) Failed patients did not or could not receive adjunctive therapy (e.g., surgery, drainage)

5 C-5 Vancomycin-treated Patients with Post-baseline Vancomycin MICs of  2 2 patients by Central Lab testing 2 patients by Central Lab testing – 1 success (cRIE) – 1 failure (cBAC; septic thrombophlebitis) 5 additional patients by Local Lab testing 5 additional patients by Local Lab testing – 1 failure (LIE; no valve replacement surgery) – 3 failures (cBAC; sternal osteomyelitis, abscesses, ulcers) – 1 failure (uBAC; abdominal wound with mesh) Failed patients did not or could not receive adjunctive therapy (e.g., surgery, drainage) Failed patients did not or could not receive adjunctive therapy (e.g., surgery, drainage)

6 C-6 Serial Passage Experiments: Magnitude of MIC Shifts Daptomycin Ciprofloxacin20 40 60 80 100 120 140 12345678910111213141516 Day Fold Change [(Strain MIC/Parent MIC)-1] 0Vancomycin

7 C-7 Genes Involved in S. aureus Susceptibility Genetic Change * Isolate Source Wild-type (Non-exposed) SAB/SAI EStudy Clinical Use Serial Passage (MIC  1) (MIC 2) (MIC 2- 4) (MIC 2- 8) (MIC 2-16) mprF- yycG--- rpoB---- rpoC---- *Genetic loci identified using whole genome comparisons between CA-MRSA MW2 and lab-derived MW2 strains with increasing daptomycin MICs mprF mutations: Part of the wild-type distribution mprF mutations: Part of the wild-type distribution yycG mutations: First unique change seen in MIC  4 clinical isolates, but not seen in wild-type isolates yycG mutations: First unique change seen in MIC  4 clinical isolates, but not seen in wild-type isolates

8 C-8 Genes Involved in S. aureus Susceptibility *Genetic loci identified using whole genome comparisons between CA-MRSA MW2 and lab-derived MW2 strains with increasing daptomycin MICs Genetic Change * Isolate Source Wild-type (Non-exposed) SAB/SAI E Study Clinical Use Serial Passage (MIC  1) (MIC 2) (MIC 2- 4) (MIC 2- 8) (MIC 2-16) mprF- yycG--- rpoB---- rpoC---- mprF mutations: Part of the wild-type distribution mprF mutations: Part of the wild-type distribution yycG mutations: First unique change seen in MIC  4 clinical isolates, but not seen in wild-type isolates yycG mutations: First unique change seen in MIC  4 clinical isolates, but not seen in wild-type isolates

9 C-9 1766 1031 453 250 275 Pharmacodynamics of S. aureus in Mice Lab-derived Isolates of CA-MRSA MW2 Median AUC = 543 µg·hr/mL with the human 6 mg/kg dose MIC Value (µg/mL) Total AUC for 3 log 10 Reduction (µg·hr/mL) 0 200 400 600 800 1000 1200 1400 1600 1800 2000 24816110100 MICs  2 respond to similar drug exposure (AUC) MICs  2 respond to similar drug exposure (AUC) MICs  4 require increasing levels of drug exposure MICs  4 require increasing levels of drug exposure

10 C-10 Efficacy in Mice Against Baseline and Post-baseline Isolates from the SAB/SAIE Study 152212105037183136172 Patient Number (Daptomycin-treated) Total Plasma AUC for 3 log 10 Reduction (µg·hr/mL) 0 250 500 750 1000 1250 1500 Baseline Post-baseline 1100 537 442 651 413 1420 713 Patient-specific AUC

11 C-11 Daptomycin Penetration into Simulated Endocardial Vegetations Daptomycin penetrates into rat fibrin clots; exerts bactericidal activity Daptomycin penetrates into rat fibrin clots; exerts bactericidal activity Mortin et al. ASM 2003; Tsuji and Rybak. AAC 2005; Caron et al. AAC 1992. T = 72h; 2 doses T = 72h; No treatment

12 C-12 Daptomycin Penetration into Simulated Endocardial Vegetations Daptomycin penetrates into rat fibrin clots; exerts bactericidal activity Daptomycin penetrates into rat fibrin clots; exerts bactericidal activity Daptomycin achieved efficacy at simulated 6 mg/kg dose Daptomycin achieved efficacy at simulated 6 mg/kg dose Mortin et al. ASM 2003; Tsuji and Rybak. AAC 2005; Caron et al. AAC 1992. T = 72h; 2 doses T = 72h; No treatment

13 C-13 Daptomycin Penetration into Simulated Endocardial Vegetations Daptomycin penetrates into rat fibrin clots; exerts bactericidal activity Daptomycin penetrates into rat fibrin clots; exerts bactericidal activity Daptomycin achieved efficacy at simulated 6 mg/kg dose Daptomycin achieved efficacy at simulated 6 mg/kg dose 14 C-daptomycin achieved homogenous penetration into rabbit vegetations 14 C-daptomycin achieved homogenous penetration into rabbit vegetations Mortin et al. ASM 2003; Tsuji and Rybak. AAC 2005; Caron et al. AAC 1992. T = 72h; 2 doses T = 72h; No treatment

14 C-14 Global Surveillance Data (MRSA) Study Year % Incidence 0 10 20 30 40 50 60 70 2000-20012002200320042005  0.12 0.25 0.5 1 2 MIC Jones et al. Annual Surveillance Reports. 2002-2005.

15 C-15 Microbiology Summary Additional investigations due to failures at MIC  2 Additional investigations due to failures at MIC  2 – Bacteria, drug, patient No decisive bacterial or daptomycin factors No decisive bacterial or daptomycin factors – No trends in surveillance – Difficult to select for large MIC increases – Incremental genetic changes – Modeling shows adequate drug exposure and penetration Patient-specific factors likely play a role Patient-specific factors likely play a role – Complicated infections and outcomes – Adjunctive care important – Similar observations with vancomycin


Download ppt "C-1 Microbiology Jeff Alder, Ph.D. Vice President, Drug Discovery and Evaluation Cubist Pharmaceuticals."

Similar presentations


Ads by Google